Galcanezumab Safe, Effective for Reducing Monthly Migraine Headache Days

In patients with chronic migraine, monthly subcutaneous injections of galcanezumab at 120- and 240-mg doses were more effective than placebo for lowering the number of monthly migraine headache days.

Source link

Related posts

Association of office-based provider visits with emergency department utilization among publicly insured stroke survivors


Editors' note: Understanding and addressing gender equity for women in neurology


Glatiramer Acetate Associated With Long-Term Disability Improvements in MS


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World